AACR meeting abstract: Projected impact of vitamin D supplementation on cancer incidence worldwide
- From: Matti Narkia <mna@xxxxxxxx>
- Date: Thu, 19 Apr 2007 01:17:05 +0300
Abstract Number: 53
Presentation Title: Projected impact of vitamin D
supplementation on cancer incidence
worldwide
Presentation Start/End Time: Sunday, Apr 15, 2007, 8:00 AM -12:00 PM
Location: Exhibit Hall, Los Angeles Convention
Center
Poster Section: 3
Poster Board Number: 16
Author Block: William B. Grant, Cedric F. Garland,
Sharif B. Mohr, Edward D. Gorham, Frank
C. Garland. Sunlight and Nutrition
Research Center, San Francisco, CA, Univ
of Calif San Diego, La Jolla, CA
This meta-analysis combined metabolic data on the dose-response
relationship of oral vitamin D supplementation to serum levels of
25-hydroxyvitamin D (25(OH)D) with data from observational studies of
serum 25-hydroxyvitamin D and risk of cancer, and incidence data for
175 countries in the GLOBOCAN database of the International Agency for
Research in Cancer. It projected levels of oral vitamin D3
supplementation that would be needed in each country to achieve
specified serum levels of 25(OH)D and cancer risk reduction, using
multiple regression, for cancers of the colon, rectum, breast,
pancreas, prostate and ovary. The projected impact of several levels
of oral supplementation with vitamin D3 on incidence rates in each
country was analyzed according to midwinter UVB irradiance, and
estimates were obtained of the projected percentage and annual number
of new cases of each cancer that could be prevented in each country
with vitamin D3 supplementation in the range of 1000-5000 IU/day of
vitamin D3, assuming the assumptions from current studies are
reasonable. The projected reduction in incidence was greatest in
countries with population centroids located at 35 degrees or higher
from the equator. The regression model predicted a 50% reduction in
incidence of colorectal cancer with 2000 IU/day of vitamin D3, and of
70% with 5000 IU/day in these countries. Similar doses were projected
to reduce incidence of cancers of the breast, ovary, pancreas, and
prostate by 15% and 33%, respectively for 2000 and 5000 IU/day. While
the projected benefit of oral supplementation would be substantial for
colorectal cancer, the expected benefit for other cancers would be
smaller. The currently established National Academy of Sciences safe
upper limit of oral intake of vitamin D (specifically, the No Adverse
Health Effect Level) is 2000 IU/day, so larger oral doses would not be
not feasible unless this upper limit is changed. However, higher
circulating levels of 25(OH)D could be obtained by seasonal
suberythemal solar UVB biosynthesis during the summer months at
temperate latitudes. Biosynthesis of vitamin D3 would be needed to
achieve reductions > 33 % for non-intestinal cancer sites. Such doses
could be obtained with solar exposures, when climatic conditions
allow, below the minimal erythemal dose of UVB, and generally no more
than 15 min/day near noon at temperate latitudes, with adequate
amounts of skin surface area (> 40%) exposed to sunlight. Such
exposures were projected to produce reductions by approximately 50% in
incidence rates of cancers of the breast, pancreas, prostate and ovary
at temperate latitudes 35 or more degrees from the equator. An
assessment also is included of risks of the above oral doses and
suberythemal solar irradiance levels, with recommendations for
adequately safe use of appropriate doses of vitamin D3 and modest
amounts of solar UVB irradiance to help reduce incidence of cancer,
while minimizing risks from its use.
--
Matti Narkia
.
- Prev by Date: Re: qPCR Newsletter
- Next by Date: Low vitamin D levels again linked to cancer risk - 2007 AACR meeting
- Previous by thread: Pfizer, merchants of death and destruction
- Next by thread: Low vitamin D levels again linked to cancer risk - 2007 AACR meeting
- Index(es):
Relevant Pages
|
